Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06806657 · ClinicalTrials.gov registry record · Phase 4
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
A Phase 4 study of Hereditary Angioedema, sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT06806657: Recruiting Phase 4 study of Hereditary Angioedema, sponsored by CSL Behring.
NCT06806657 is a Phase 4 study of Hereditary Angioedema that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 30 participants, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (59% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06806657, a Phase 4 study of Hereditary Angioedema, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
Conditions Studied
Interventions
- BIOLOGICAL Garadacimab
Study Locations (10)
Other
- Clinique Spécialisée en Allergie de la Capitale - Québec
- HZRM Hämophilie Zentrum Rhein Main GmbH - Frankfurt
- Hautklinik und Poliklinik der Universitätsklinik Mainz - Mainz
California
- Donald Levy M.D. - Orange
- Raffi Tachdjian MD, Inc. - Santa Monica
Arizona
- Research Solutions of Arizona - Litchfield Park
Arkansas
- Allergy and Asthma Clinic of Northwest Arkansas - Bentonville
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Utah
- Chronicle Bio - West Valley City
Quebec
- Montreal Clinical Research Institute - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 4 |
What NCT06806657 shows while recruiting
NCT06806657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 1 intervention - of which Garadacimab is the first listed.
NCT06806657 lists 10 locations in 7 states (Other, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT06806657 about?
NCT06806657 is a clinical study titled "Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab". This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 month...
What is the current status of trial NCT06806657?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-03-19. Estimated completion is 2026-06-15.
What conditions does trial NCT06806657 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT06806657?
The interventions under investigation include: Garadacimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06806657?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06806657 being conducted?
This trial has 10 study locations across Arizona, Arkansas, California, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06806657's enrollment target sits among peer trials
30 11th of 14 higher than 4 of 14 other Hereditary Angioedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hereditary Angioedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
-
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI